Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Higher sales of blockbuster cancer drug Keytruda weigh against a 17% slump in sales of HPV vaccine Gardasil Merck's stock ... $9.03 on sales of $64.1 billion to $65.6 billion.

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.

For 2025 Merck, based in , Rahway, New Jersey, expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 billion in sales. Analysts had been projecting ...

Merck on issued full-year 2025 revenue guidance ... The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 billion, lower than the $67.31 billion that analysts surveyed by ...

Six analysts surveyed by Zacks expected $15.55 billion. Merck expects full-year earnings in the range of $8.88 to $9.03 per share, with revenue in the range of $64.1 billion to $65.6 billion.

Guidance: Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion, including a negative impact of foreign exchange of approximately 2% at mid ...